Flap endonuclease 1 (Fen1) and exonuclease 1 (Exo1) have sequence homology and similar nuclease capabilities. Both function in multiple pathways of DNA metabolism, but appear to have distinct in vivo nucleic acid substrates, and therefore distinct metabolic roles. When combined with Apc   1638N 
, Fen1 promotes tumor progression. Because of functional similarity to Fen1, and because Exo1 is involved in DNA mismatch repair (MMR) by interaction with Msh2 and Mlh1, genes that cause hereditary nonpolyposis colorectal cancer (HNPCC), we investigated the possibility that Exo1 might also act as a modifier to Apc 1638N . We present evidence that mice with combined mutations in Apc 1638N and Exo1 and Apc
1638N
, Exo1 and Fen1 genes show moderate increased tumor incidence and multiplicity in comparison to Apc 1638N siblings, implying a low penetrance role for Exo1 in early gastrointestinal (GI) tumorigenesis. Despite a decrease in median survival (10 months) in Apc 1638N Exo1 mice, their tumors do not progress any more rapidly than those of Apc
Introduction
Mutations in the MutS and MutL homologs MSH2 and MLH1 account for almost two-thirds of all hereditary nonpolyposis colorectal cancers (HNPCC) (Peltomaki and Vasen, 1997) . MSH2 and MLH1 are members of a family of genes whose products are necessary for the repair of single nucleotide or small insertion/deletion mismatches in DNA. Mutations in MSH2 and MLH1 cause increased mutation rates in mammalian cells, which in turn results in increased cancer susceptibility. Mismatch repair (MMR) involves several different steps and each step requires several different gene products. MSH2 and MLH1 are involved in mismatch recognition and in signaling a cellular response that is necessary to complete the repair process. Since MSH2 and MLH1 cause HNPCC, it is reasonable to assume that mutations in other genes whose products are essential for DNA mismatch repair would also be involved in tumor susceptibility or tumor progression. Two such genes, with possible redundant endo/exonuclease activities that act in MMR, are exonuclease 1 (Exo1) and flap endonuclease 1 (Fen1).
EXO1 is a 5 0 to 3 0 exonuclease with suspected 3 0 to 5 0 exonuclease activity (Dzantiev et al., 2004) that interacts with the MMR complex. It participates both by catalyzing excision of the newly synthesized mismatch containing DNA strand and by stabilizing higher order complexes of MMR proteins (Tishkoff et al., 1997; Rudolph et al., 1998; Schmutte et al., 1998 Schmutte et al., , 2001 Tran et al., 1999 Tran et al., , 2001 Sokolsky and Alani, 2000; Amin et al., 2001; Nielsen et al., 2004) . FEN1 has both endonuclease and exonuclease activity and is an integral part of DNA replication and repair. Its main role in replication is the excision of Okazaki fragments during lagging strand synthesis, and it functions in long patch base excision repair. Lack of FEN1 is known to lead to duplications and deletions (Liu et al., 2004) . EXO1 and FEN1 are members of the RAD2 family of nucleases and function not only in repair but also in DNA replication, meiosis, recombination and telomere integrity (for a review see Tran et al., 2004) . Both Exo1 (RAD2 class III) and Fen1 (RAD2 class II) have 5 0 to 3 0 exonuclease and flap endonuclease activities (Lee and Wilson, 1999; Tran et al., 2002) . Analysis of mutations in conserved domains of Exo1 and Fen1 indicates that the two proteins have distinctly different cellular functions because identical mutations in these regions lead to disparate phenotypes (Lee Bi et al., 2002) . Several groups have examined the role of EXO1 in colon cancer predisposition. Wu et al. (2001) identified EXO1 mutations in HNPCC families reporting loss of heterozygosity (LOH) of the mutant allele in tumors; and EXO1 was proposed to be a high or moderate penetrance colorectal cancer (CRC) predisposition gene (Wu et al., 2001) . These data were unusual because the tumor cells reportedly had lost the mutated allele rather than the wild-type (WT) allele. The investigators argued that complete loss of EXO1 might be lethal, but this suggestion was at odds with viability of Exo1 null yeast and the Exo1 mutant mice (Wei et al., 2003; Tran et al., 2004) . Because the variants that were reported by Wu et al. (2001) were subsequently found to be common variants in normal populations, several investigators concluded that EXO1 probably does not play a major causative role in classical HNPCC (Alam et al., 2003; Jagmohan-Changur et al., 2003) . However, recently two EXO1 single nucleotide polymorphisms (SNPs) have been shown to have a significant association with the development of CRC (Yamamoto et al., 2005) . That EXO1 may play a role in mammalian carcinogenesis as a low penetrance or modifying gene has not been excluded in any of these studies, and a role for EXO1 in CRC remains undefined.
Exo1 knockout mice carrying a deletion in exon 6 (hereafter referred to as Exo1/dex 6) spanning a significant portion of the Rad2 domain have a cancer predisposition as they develop lymphomas and a meiotic phenotype (Wei et al., 2003) . MMR is impaired in these mice but an increased incidence in gastrointestinal (GI) tumors is not observed (Edelmann and Edelmann, 2004) . Humoral immunity in Exo1/dex 6 À/À mice is defective due to reduction in somatic hypermutation (SHM) and class-switch recombination (CSR) in B lymphocytes.
Fen1 is essential for normal development, as mice that are homozygous for a knockout allele of Fen1 (B6.CgFen1 tm1Rak ) do not survive embryogenesis (Kucherlapati et al., 2002) . Heterozygous animals appear normal and do not develop colorectal tumors, however, when combined with the Apc 1638N mutation, double heterozygous mice have increased numbers of adenocarcinomas with microsatellite instability (MSI) and decreased median survival (10 months). Apc 1638N heterozygous animals have previously been shown to be cancer prone (Fodde et al., 1994 Apc  1638N mice We generated two groups of mice, in similar genetic backgrounds, designated EFH and AEFH (total n ¼ 507), as described in the Materials and methods section. Exo1 þ /À Fen1 þ /À animals from the EFH group are hereafter referred to as 'EF'. EF mice were intercrossed and the offspring were used to generate survival curves. The AEFH cohort was generated through mating Apc 1638N þ /À animals with EF mice. A total of 90 mice were examined for GI tumors. They were divided into two groups designated 'young' (mice 6 months of age or younger) and 'senior' (over 6 months of age). The mean age of each group is shown in Table 1 . The two groups were combined to form a third called 'overall'. Tumor incidence and type in each of the groups are summarized in Table 1 . An unusual ossifying fibroma of the jaw with psammoma bodies was found in some of these mice (Figure 2 ). This tumor has been observed recently with low penetrance in mice that are heterozygous for Apc 1638N (R Bronson, unpublished results). 
Results

Effect of Exo1 mutation in
Two sets of data indicate that tumor initiation in AE and AEF mice is increased over Apc 1638N mice. 'Overall' (carcinomas plus adenomas) tumor incidence (Table 1) indicates that both AE and AEF mice have higher tumor incidence than A alone (P>0.05). Tumor multiplicity in AE and AEF 'overall' animals is increased (Po0.05; Table 2 ).
Histological analysis was carried out on 222 of the 285 GI tumors, providing confirmation of grading for 78% of the total number of tumors. Results from this analysis are shown in Table 3 . In 'senior' AE animals, there was a 63% decrease in adenocarcinomas over Apc 1638N animals without significance, and an increase in adenomas over Apc 1638N mice with significance (Po0.05). Carcinoma multiplicity was 70% decreased with no statistical significance, and adenoma multiplicity in AE 'senior' mice was increased over Apc 1638N siblings with significance (P ¼ 0.04). Representative pictures of adenoma and adenocarcinomas from AE and AEF mice are shown in Figure 2 . These results suggest that the reduced survival of the AE mice is not exclusively due to accelerated tumor progression, but may result from other causes. Since Exo1 has a predicted effect on the immune system, we examined the spleens of these mice.
Fifty-seven spleens from EFH and AEFH mice of various genotypes were examined in a blind study for abnormalities. Representative results are shown in Figure 3 and summarized in Table 4 . A low percentage of both Apc 1638N þ /À (A) and Exo1 þ /À (E) mice had enlarged spleens due to increased hematopoiesis with some reduction in lymphoid tissues. AE and AEF spleens had a higher incidence of spleen enlargement due to increased hematopoiesis and severe reduction of lymphoid tissues.
Full necropsies of six moribund AE mice (mean age 8 months), revealed other histo-pathological features that are consistent with immune deficiency in these animals. Bone marrow sections showed increased neutrophils or neutrophil precursors consistent with infection in five out of six animals examined. Blood smears from four out of eight AE mice (50%) showed hemolytic anemia consistent with septicemia ( Figure 2 ). Four out of six small intestines had inflammation or edema. In one case, fungal hyphae were observed along with edema in intestinal villi, consistent with fungal enteritis. In another mouse, hydropic changes in the kidney consistent with bacterial endotoxin production were observed along with inflammation and sloughing of intestinal mucosa. A third case showed ulceration of the small intestine, unrelated to tumorigenesis, with subsequent inflammation and peritonitis. The liver of this animal was necrotic, consistent with infection. A fourth animal had lymph nodes lacking germinal centers, extramedullary hematopoiesis in the liver and neutrophil increase in bone marrow. A large hair follicle tumor 2-3 cm in diameter was also found in this mouse. All of these results suggest that the premature death of the AE mice may be the result of both tumor burden and impaired immune function.
Effect of Fen1 mutation in Apc 1638N Exo1 mice We have previously reported on the effect of combining the Apc 1638N þ /À mutant mice with Fen1 þ /À mutant mice (Kucherlapati et al., 2002) . To examine possible synergies in the function of Exo1 and Fen1 gene products, we generated mice with mutations in the Apc, Exo1 and Fen1 genes. AEF mutant mice have a median survival of 18 months that is lower relative to EF and higher with respect to Apc 1638N and AE genotypes (Figure 1 ). The tumor incidence for AEF mice is greater than that observed in Apc 1638N mice (Table 2) . AEF mice also have up to a twofold increase in tumor multiplicity over Apc 1638N mice (Table 3) . Senior mice have a significantly greater difference in tumor progression compared to AE animals. They show comparable patterns of progression toward adenocarcinomas as Apc 1638N mice. Like AE animals, the spleens of AEF mice are not normal and have decreased lymphoid tissues and increased hematopoiesis. Full necropsies of six moribund AEF mice (12.2 months at death) were conducted. Five of six animals (83%) had GI polyps and adenocarcinomas. Two animals (33%) had the unusual ossifying fibroma of the jaw with psammoma bodies described above. Two animals (33%) had septicemia subsequent to ulceration of the small intestine. One animal (17%) had histiocytic sarcoma, another had an unusual solid mammary tumor with tubular and squamous differentiation and a third (17%) had moist dermatitis. Two animals (33%) had atrophic thymi.
Mild predisposition for intussusception in Exo1 and Fen1 mice In a group of 17 AE mice examined for GI tumors, three (18%) were found to have intussusceptions (Figure 2 ). Examination of a portion of past dissection records showed documentation of one AEF mouse and one Apc 1638N Fen1 mouse with intussusceptions. 
LOH of Exo1 not found in tumors
To elucidate further the underlying mechanisms involving tumor progression, we looked for LOH of the WT Exo1 allele in AE and AEF tumors. Eighteen AEF tumors, eight AE tumors and six Apc 1638N tumors were examined by PCR analysis for the presence of the WT allele using genotyping primers described in the Materials and methods section. LOH was not observed in any tumor DNA tested. Multiple exons from four AEF and four AE tumors were PCR amplified and sequenced , AF or AEF mice (Table 5) . Tumors from AEF mice had a similar incidence of Apc truncation mutations. Sequence analysis (Table 6 ) revealed an increase in insertion mutations (50%) within repetitive sequences. These mutations do not commonly occur in Apc 1638N tumors, and are consistent with mutations that are the result of Fen1 deletion in lower eukaryotes. The substitution mutations found in both AE and AEF tumors were similar to those found in tumors from Apc 1638N mice.
Mice with Exo1 and Fen1 mutations develop hematopoietic tumors
Examination of many different organs of five moribund mice doubly heterozygous for Exo1 and Fen1 revealed that four out of five animals developed hemopoietic tumors (80% penetrance). Two out of five had histiocytic sarcoma (40% penetrance), one animal had a B-cell lymphoma (20%) and one animal had a mixed blood dyscrasia involving macrophages, eosinophils, neutrophils and plasma cells (20%). Tumors of the GI tract were not observed.
Discussion
We have examined mice with heterozygous mutations in the Apc 1638N Exo1 and Fen1 genes, and found differences in tumor incidence, multiplicity and progression that correlate with specific genotypes. AE and AEF mice both have a modest, but significant increase in tumor incidence and multiplicity compared to Apc 1638N mice. This implies that Exo1 mutations may indeed modify Apc-driven tumorigenesis. It is consistent with a report (Yamamoto et al., 2005) that EXO1 SNPs in the population have significant association with the development of CRC. Since Fen1 þ /À has been previously shown to have no effect on tumor initiation or multiplicity, the observed increases in AEF mice are most likely attributable to the Exo1/dex 6 þ /À mutation alone. Neither Exo1/dex 6 þ /À nor Fen1 þ /À mutations cause CRC in measurable numbers in the murine GI tract though Exo1 functions through MMR, the rate of mutation caused by its deficiency is likely below the level necessary to alter both Apc alleles and lead to tumor formation. However, when Apc is altered in the germline, somatic mutations in the second Apc allele that result from Exo1 deficiency may result in increased tumor incidence and multiplicity.
The lack of tumor progression in AE mice relative to tumors from A and AEF genotypes, despite increase in tumor multiplicity, suggests two opposing roles for Exo1. Reduced activity of this enzyme may result in Table 4 Incidence of spleen abnormalities in EFH and AEFH mice Genotype n Number of mice with spleen abnormalities (%)
Number of mice with different degrees of spleen abnormalities (%)
A: Slightly enlarged spleen with increased hematopoiesis, normal amount of lymphoid tissue. B: Enlarged spleen with increased hematopoiesis, normal amount of lymphoid tissue. C: Slightly enlarged spleen with increased hematopoiesis, reduced amount of lymphoid tissue. D: Enlarged spleen with increased hematopoiesis, no lymphoid tissue.
1 Compared with wild type P ¼ 0.0124 by Fisher's exact probability (two-tailed).
2 Compared with wild type P ¼ 0.0152 by Fisher's exact probability (two-tailed). increased levels of mutation during MMR that leads to increased incidence in tumor multiplicity. However, reduction in its levels may also lead to reduced cellular proliferation, resulting in slower tumor progression, supporting the hypothesis that these enzymes may function redundantly in proliferation. These opposing roles are further substantiated by the decrease in truncation mutations and lack of MSI in the AE tumors. While tumor burden may play a role in pathogenesis of AE animals, we find immune impairment and infection to be a contributing factor for their reduced survival. This reduction in immunity is substantiated by the existence of documented immune phenotypes in mouse models with mutations in either Apc or Exo1. Apc 1638N mice undergo lymphocyte depletion (Coletta et al., 2004; Gounari et al., 2005) , and have defects in cellular immunity. Bardwell et al. (2004) have demonstrated that Exo1/dex six mice have deficiency in somatic hypermutation and class switching in B lymphocytes.
The significant increase in median survival of AEF mice relative to the AE animals suggests reduction in the levels of Fen1 compensates for Exo1 reduction by an unknown mechanism. It is possible that the relative stoichiometry of these proteins is important for normal function of the MMR and replication complexes in different tissues. The progression of tumors from AEF mice into adenocarcinomas can be explained by the fact that the mice live longer, thereby providing an opportunity for the tumors to progress. The fact that reduction in Fen1 also results in an increased level of mutation may also contribute to the tumor progression. In previous studies, (Kucherlapati et al., 2002 ) the remaining Fen1 allele in tumors was examined in 15 tumors by sequencing both coding region and transcriptional elements. The WT Fen1 allele was found intact in all tumors and it was concluded that haplo-insufficiency was responsible for the advance in tumor progression and MSI, not LOH. This was in agreement with the fact that mutations in FEN1 are not found in tumors and that alterations in expression are, and that FEN1 is an integral part of DNA lagging strand synthesis. We were also unable to find LOH of Exo1 in AE and AEF tumors in this study, or mutations in the remaining allele by sequencing. We cannot rule out the possibility that the second Exo1 allele maybe inactive in some tumors, or that the altered allele has undergone further rearrangement. However, since Exo1 is highly expressed referred hereafter as Fen1 þ /À) are available through the Mouse Repository of the Mouse Models of Human Cancers Consortium, and are described previously (Kucherlapati et al., 2002) . Generation of mice with the Exo1 null allele (Exo1 tm1Wed/W þ , referred to as Exo1 þ /À) is described by Wei et al. (2003) . The Apc 1638N allele is described by Fodde et al. (1994) . Apc 1638N mice spontaneously develop intestinal and colonic polyps and colon cancer. The founder mice carrying the Fen1 and Apc 1638N alleles were on a C57/Bl6 background. The founder Exo1 mice were of a mixed genetic background estimated to be 60% C57/Bl6, 37.5% 129/SV and 2.5% SJL/J. All offspring examined for GI tumorigenesis and general pathology were siblings from the AEFH cohort (matings are described in the 'Results' section) and therefore on the same genetic background. All animals were maintained in Association for Assessment and Accreditation of Laboratory Animal Care-approved facility under barrier conditions. Mice were fed Purina's Picolab Mouse Diet 20 Food Type 5058 (http:// www.labdiet.com/indexlabdiethome.htm).
Genotyping of offspring
Animals were genotyped for Fen1, Exo1 and Apc 1638N status by PCR as described previously (Fodde et al., 1994; Kucherlapati et al., 2002; Wei et al., 2003) . DNA was made from tail clippings of animals at 10 days of age using DNAeasy Kits from Qiagen (Valencia, CA, USA).
Generation of survival curves
Birth and death dates for animals were recorded routinely. Prism software by GraphPad was used to generate survival curves.
Histopathological analysis and analysis of GI tumors Tissue samples were examined for tumors after gross dissection and then fixed in Bouin's Fixative Solution (RICCA Chemical Co., Arlington, TX, USA) followed by embedding in paraffin blocks and serial sectioning (5 mm). Both normal and neoplastic sections were stained with hematoxylin and eosin (H&E) and examined to determine pathology.
The GI tract was observed systematically in a separate cohort of mice. Animals were euthanized and the entire GI tract removed, opened longitudinally and fixed in 10% neutralbuffered formalin. The gross specimens were examined under a dissecting microscope for tumors, and the number and location of tumors was recorded. Representative tumors were chosen for histological and molecular analysis. Sections were stained with H&E and observed for histological diagnosis. Early invasive adenocarcinomas were those that had invaded into the submucosa, and invasive adenocarcinomas were those that had invaded into the muscularis and beyond. Microadenomas were counted in five serial sections of flat mucosa adjacent to tumors. The Fisher's exact probability and w 2 tests were used for the analysis of tumor incidence, and the Mann-Whitney and binomial exact calculation tests for tumor multiplicity.
MSI analysis DNA extracted from tumor tissue was used for PCR amplification under limiting dilution conditions (Edelmann et al., 2000) . Approximately 25-30 reactions were performed on each sample after dilution to 10 À5 . The D7Mit91 locus was amplified by PCR and products separated on a denaturing polyacrylamide gel, dried onto Whatman paper and autoradiographed. Instability was judged by determining the proportion of PCR that contained microsatellite allele that differed from the WT allele.
Analysis of Apc truncation mutations
The analysis of mutations on the second Apc allele has been fully described in Edelmann et al. (1999) .
